 New York, New York--Newsfile Corp. - February 23, 2021 - PCG Digital -- Operational efficiency and sound financial management lead to positive results. That statement sums up why Soligenix NASDAQ: SNGX is fast approaching a new drug application NDA submission and potential FDA approval for SGX301 synthetic hypericin, a photodynamic treatment option to battle the debilitating effects of cutaneous T-Cell lymphoma CTCL.The most recent treatment option in their rare disease pipeline, SGX301, will potentially... 